Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

Jürgen C. Becker, Selma Ugurel, Ulrike Leiter, Friedegund Meier, Ralf Gutzmer, Sebastian Haferkamp, Lisa Zimmer, Elisabeth Livingstone, Thomas Eigentler, Axel Hauschild, Felix Kiecker, Jessica C. Hassel, Peter Mohr, Michael Fluck, Ioannis Thomas, Marlene Garzarolli, Imke Grimmelmann, Konstantin Drexler, Alexandra N Spillner, Sebastian Eckhardt, Dirk Schadendorf, Alexander C. J. van Akkooi, Winan J. van Houdt, Tabea Wilhelm, Kimberley Farmer, Claas Ulrich, Thilo Gambichler, Leonie Bluhm, Heidemarie Schinagl, Ivonne Kellner, Rudolf Herbst, Frank Meiß, David Rafei‐Shamsabadi, Sabine Sell, Martin Kaatz, Lena M. Wulfken, Martin Hartmann, Katharina C. Kähler, Mirjana Ziemer, Jan C. Simon, Patrick Terheyden, Diamant Thaçi, Carmen Loquai, Heidrun Mitzel-Rink, Stephan Grabbe, Henner Stege, Maria Rita Gaiser, Jochen Utikal, Carola Berking, Lucie Heinzerling, Max Schlaak, Dirk Tomsitz, Jörg Dyballa, Nina Magnolo, Carsten Weishaupt, Mark Berneburg, Claus Garbe, Lukas Flatz, Anja Gesierich, Bastian Schilling